PDF(Pubmed)
Abstract：
UNASSIGNED: The most effective method and length of time for administering adjuvant immunotherapy after surgery for non-small cell lung cancer (NSCLC) are still unknown. Various clinical trials have utilized diverse strategies for adjuvant treatment. In this case, we explore the potential benefits of neoadjuvant immunotherapy combined with chemotherapy in managing locally advanced lung squamous carcinoma, which often poses challenges for treatment. This multimodal approach aims to downstage tumors and optimize surgical outcomes.
UNASSIGNED: Following a diagnosis of stage IIIB lung cancer, the patient underwent three cycles of neoadjuvant therapy using sintilimab, Abraxane, and Lobaplatin, resulting in a significant 45% reduction in tumor size. Subsequently, a right lower lobe lobectomy and systematic lymphadenectomy were performed using a uniportal video-assisted thoracic surgery (VATS) approach. Postoperative analysis revealed negative lymph nodes, with only a 5-mm residual tumor in the tumor bed, downstaging the cancer to IA1. Remarkably, the patient experienced a smooth recovery without any postoperative complications. One cycle of adjuvant therapy was administered following the operation to further support the patient\'s recovery and minimize the risk of disease recurrence. This comprehensive treatment approach underscores the importance of neoadjuvant therapy in optimizing surgical outcomes and improving long-term prognosis for patients with locally advanced lung cancer.
UNASSIGNED: For patients with stage III locally advanced lung squamous carcinoma, the combination of Sintilimab and Platinum-based drugs can be used as a neoadjuvant therapy which can reduce the difficulty of the operation.
UNASSIGNED: Following a diagnosis of stage IIIB lung cancer, the patient underwent three cycles of neoadjuvant therapy using sintilimab, Abraxane, and Lobaplatin, resulting in a significant 45% reduction in tumor size. Subsequently, a right lower lobe lobectomy and systematic lymphadenectomy were performed using a uniportal video-assisted thoracic surgery (VATS) approach. Postoperative analysis revealed negative lymph nodes, with only a 5-mm residual tumor in the tumor bed, downstaging the cancer to IA1. Remarkably, the patient experienced a smooth recovery without any postoperative complications. One cycle of adjuvant therapy was administered following the operation to further support the patient\'s recovery and minimize the risk of disease recurrence. This comprehensive treatment approach underscores the importance of neoadjuvant therapy in optimizing surgical outcomes and improving long-term prognosis for patients with locally advanced lung cancer.
UNASSIGNED: For patients with stage III locally advanced lung squamous carcinoma, the combination of Sintilimab and Platinum-based drugs can be used as a neoadjuvant therapy which can reduce the difficulty of the operation.
摘要：
■非小细胞肺癌（NSCLC）手术后给予辅助免疫疗法的最有效方法和时间长短仍然未知。各种临床试验已经利用不同的辅助治疗策略。在这种情况下,我们探讨新辅助免疫治疗联合化疗治疗局部晚期肺鳞癌的潜在益处,这往往给治疗带来挑战。这种多模式方法旨在降低肿瘤分期并优化手术结果。
■诊断为IIIB期肺癌后，患者接受了三个周期的新辅助治疗，使用sintilimab，Abraxane,还有洛铂,导致肿瘤大小显著减少45%。随后，我们采用单通道电视胸腔镜手术(VATS)方法进行了右下叶肺叶切除术和系统性淋巴结清扫术.术后分析显示淋巴结阴性，瘤床上只有一个5毫米的残留肿瘤，将癌症降级为IA1。值得注意的是,患者恢复顺利，没有任何术后并发症。手术后给予一个周期的辅助治疗，以进一步支持患者的康复并将疾病复发的风险降至最低。这种综合治疗方法强调了新辅助治疗在优化手术结果和改善局部晚期肺癌患者长期预后方面的重要性。
■对于III期局部晚期肺鳞癌患者，Sindilimab和铂类药物的联合应用可以作为新辅助治疗，可以降低手术难度。
■诊断为IIIB期肺癌后，患者接受了三个周期的新辅助治疗，使用sintilimab，Abraxane,还有洛铂,导致肿瘤大小显著减少45%。随后，我们采用单通道电视胸腔镜手术(VATS)方法进行了右下叶肺叶切除术和系统性淋巴结清扫术.术后分析显示淋巴结阴性，瘤床上只有一个5毫米的残留肿瘤，将癌症降级为IA1。值得注意的是,患者恢复顺利，没有任何术后并发症。手术后给予一个周期的辅助治疗，以进一步支持患者的康复并将疾病复发的风险降至最低。这种综合治疗方法强调了新辅助治疗在优化手术结果和改善局部晚期肺癌患者长期预后方面的重要性。
■对于III期局部晚期肺鳞癌患者，Sindilimab和铂类药物的联合应用可以作为新辅助治疗，可以降低手术难度。
